New Rule: Matt Harman Talks About Employer Interest in Biosimilar Promotion

Matt Harman talks about employer interest in biosimilar promotion and how the FDA's new biologics pathway change will affect interest levels, during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California.

Matt Harman is the senior director of pharmacy at Employers Health.


Please discuss the interest level among employers in promoting biosimilar adoption.

There's a large interest in biosimilars for employers, because when you look at [what] employers spend, about 40 to 50% of costs are on specialty medications, and that's why we think of biosimilars as maybe the saviors of specialities, since they can really help reduce the cost to those employers. You look at a client's top 25 drugs, roughly half of them have potential for biosimilars. Some are already approved but not yet on the market. And then, when you think about insulins or growth hormones, with the new rule changes for potential biosimilars, for those products, there's a lot of interest. We really need these type of products to create competition to reduce the specialty trends that have been going up and up and up each year. So, I think there's a very high interest.

Related Videos
Michael Kleinrock
Here are the top 5 biosimilar articles for the week of February 13th, 2023.
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Ryan Haumschild, PharmD, MS, MBA
Ryan Haumdschild, PharmD
banner for the ophthalmology linkedin live event sponsored by the samsung bioepis in partnership with the center for biosimilars
Ryan Haumschild, PharmD
Related Content
© 2023 MJH Life Sciences

All rights reserved.